Biogen Inc. has released preliminary estimates for its second quarter 2025 financial results, indicating an inclusion of approximately $46 million in acquired in-process research and development, upfront and milestone expenses on a pre-tax basis. This charge is expected to impact both GAAP and non-GAAP net income per diluted share for the second quarter of 2025 by approximately ($0.26) per share. These figures reflect the company's ongoing financial activities related to collaboration and license agreements. Final results for the quarter ended June 30, 2025, are pending completion of Biogen's financial statement closing procedures and may differ from these preliminary estimates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.